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Summary  The  number  of  children  in  need  of  mechanical  circulatory  support  has  increased
substantially  over  the  last  two  decades,  due  to  the  technological  progress  made  in  surgery
and intensive  care,  leading  to  improved  survival  of  patients  with  congenital  heart  disease.
In addition,  primary  myocardial  dysfunction  related  to  myocarditis  or  dilated  cardiomyopa-
thy may  cause  end-stage  cardiac  failure  in  children  or  infants,  although  not  as  frequently  as  in
adults. The  need  for  mechanical  circulatory  support  may  be  either  temporary  until  spontaneous
myocardial  recovery,  as  in  postcardiotomy  cardiac  failure,  or  prolonged  until  heart  transplan-
tation in  the  absence  of  recovery.  Two  types  of  mechanical  circulatory  devices  are  suitable  for
the paediatric  population:  extracorporeal  membrane  oxygenation  for  short-term  support;  and
ventricular assist  devices  for  long-term  support  as  a  bridge  to  transplantation.  The  aim  of  this
review is  to  describe  the  speciﬁc  issues  related  to  paediatric  mechanical  circulatory  support
and the  different  types  of  devices  available,  to  report  on  their  rapidly  growing  use  worldwide
and on  the  outcomes  for  each  indication  and  type  of  device,  and  to  provide  a  perspective  on
the future  developments  and  remaining  challenges  in  this  ﬁeld.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.Abbreviations: CHD, congenital heart disease; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; ECPR,
xtracorporeal cardiopulmonary resuscitation; MCS, mechanical circulatory support; VAD, ventricular assist device.
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Résumé  Le  nombre  d’enfants  ayant  besoin  d’une  assistance  circulatoire  augmente  régulière-
ment depuis  20  ans,  en  raison  des  progrès  techniques  de  la  chirurgie  cardiaque  et  de  la
réanimation  qui  ont  permis  d’améliorer  la  survie  des  patients  atteints  de  cardiopathie  con-
génitale. De  plus,  les  enfants  peuvent  être  atteints  de  dysfonction  myocardique  primitive  liée
à une  myocardiopathie  dilatée  ou  une  myocardite,  responsable  d’insufﬁsance  cardiaque  termi-
nale. L’indication  d’assistance  peut  être  de  courte  durée  en  cas  de  dysfonction  myocardique
transitoire  comme  après  une  chirurgie  cardiaque  par  exemple,  ou  prolongée  jusqu’à  une  trans-
plantation  cardiaque  en  l’absence  de  récupération  myocardique.  Deux  types  de  dispositifs
d’assistance  principaux  sont  utilisables  en  pédiatrie  :  l’oxygénation  extracorporelle  par  mem-
brane pour  une  assistance  de  courte  durée  et  les  dispositifs  d’assistance  ventriculaire  pour  un
support prolongé  en  pont  vers  la  transplantation.  Le  but  de  cette  revue  est  de  décrire  les  difﬁ-
cultés spéciﬁques  de  l’assistance  circulatoire  pédiatrique,  les  différents  dispositifs  disponibles,
l’augmentation  rapide  et  généralisée  du  recours  à  ces  techniques,  les  résultats  pour  chaque
indication  et  chaque  type  d’assistance,  et  enﬁn  de  donner  une  perspective  sur  les  futurs
développements  et  les  déﬁs  restant  à  relever.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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The  number  of  children  being  hospitalized  for  end-stage
heart  failure,  secondary  to  congenital  heart  disease  (CHD)
or  primary  myocardial  disease,  is  increasing.  This  number
is  expected  to  rise  even  higher  in  the  coming  years,  as
the  number  of  patients  with  CHD  reaching  adulthood  is
increasing  steadily.  While  heart  transplantation  remains  the
mainstay  of  treatment  for  refractory  heart  failure,  with  gen-
erally  good  long-term  survival  approaching  70%  at  10  years,
the  mortality  rate  while  awaiting  a  suitable  organ  exceeds
20%.  Indeed,  the  number  of  heart  transplantations  world-
wide  has  remained  stagnant  for  the  last  10  years.  Durable
mechanical  circulatory  support  (MCS)  for  the  failing  heart
has  been  used  extensively  as  a  bridge  to  heart  transplanta-
tion  in  adult  patients,  as  numerous  ventricular  assist  devices
(VADs)  have  been  available  for  several  decades  to  provide
both  temporary  and  long-term  support.  Paediatric  patients,
because  of  their  smaller  size  and  their  often  complex
anatomy  and  physiology,  present  a  unique  set  of  challenges
that  has  slowed  the  development  of  MCS  in  this  population.
The  use  of  extracorporeal  membrane  oxygenation  (ECMO),
which  has  long  been  the  sole  means  of  mechanical  support
for  paediatric  patients  with  end-stage  cardiac  failure,  has
increased  steadily  since  the  1980s  and  has  contributed  to
improve  survival  signiﬁcantly  [1].  However,  the  short  dura-
tion  of  support  provided  by  ECMO  (typically  10—20  days)  is  a
major  limitation,  considering  the  current  waiting  times  on
the  transplant  list.  The  use  of  long-term  support  with  VADs
in  children  as  a  bridge  to  transplantation  remained  sporadic
until  the  early  2000s.  However,  thanks  to  the  development
of  suitable  devices  for  infants  and  small  children,  mainly
the  Berlin  Heart  EXCOR  Paediatric  VAD  (Berlin  Heart  AG,
Berlin,  Germany),  implantation  of  VADs  in  children  has  grown
exponentially  in  recent  years  [2].
Paediatric speciﬁcities
There  are  several  critical  issues  to  be  considered  for  the
successful  support  of  children.  The  ﬁrst  issue  is  the  minia-
turization  of  the  device  to  make  it  suitable  for  a  child’s
M
A
cize,  requiring  a  good  understanding  of  the  ﬂow  devices  with
egard  to  haemolysis,  thrombogenesis,  immuno-activation
activation  of  an  inﬂammatory  cascade)  and  effective
nergy  transmission  (speciﬁcally  continuous  compared  with
ulsatile).  For  geometric  reasons,  miniaturization  of  the
evice  results  in  increased  surface  area  per  blood  volume,
hich,  in  combination  with  lower  ﬂow  rates  than  in  adults,
ncreases  the  risk  of  thrombogenesis.  In  addition,  the  narrow
ize  of  the  openings  and  cannulae  causes  high  shear  stress
uring  the  passage  of  red  blood  cells  through  the  device,
romoting  haemolysis.  Finally,  miniaturization  of  all  compo-
ents  of  the  system  reduces  energy  transmission  efﬁciency.
wing  to  all  these  challenges,  paediatric  patients  are  more
ikely  to  beneﬁt  from  pulsatile  operation  mode  than  adults.
Another  aspect  of  paediatric  MCS  is  that  the  pathophysi-
logy  of  heart  failure  is  different  in  children  than  in  adults.
solated  left  ventricular  dysfunction  is  rare  in  children,  in
hom  the  need  for  circulatory  support  is  often  due  to  a
ombination  of  right  ventricular  failure,  hypoxaemia  and
ulmonary  hypertension.  In  this  setting,  ECMO  is  the  prefer-
ble  option.  Left  VAD  is  used  in  patients  with  predominantly
eft  ventricular  failure  and  normal  lung  function.  Biventric-
lar  support  is  more  commonly  necessary  in  children  with
eart  failure  secondary  to  CHD.  Children  with  CHD  also
ave  intrinsic  anatomical  variations  that  can  pose  signiﬁ-
ant  difﬁculty  in  cannulation  for  MCS  (e.g.  single  ventricle,
bnormal  systemic  venous  return,  etc.).  From  a  physiologi-
al  standpoint,  previous  surgery  may  further  jeopardize  the
pplication  of  MCS  (e.g.  systemic-pulmonary  shunts,  discon-
ected  vena  cavae  in  Glenn  or  Fontan  circulations,  etc.).
ndications
he  two  main  indications  for  MCS  in  children  are  cardiac
edical  failure  and  postcardiotomy  (post-surgical)  cardiac
ysfunction.edical indications
lthough  not  as  common  in  children  as  in  adults,  dilated
ardiomyopathies  are  the  leading  cause  of  heart  failure
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n  children  without  CHD  and  are  the  most  common  indi-
ation  for  non-surgical  MCS.  According  to  the  Paediatric
ardiomyopathy  Registry,  the  annual  incidence  of  dilated
ardiomyopathies  in  children  aged  <  18  years  is  0.57  cases
er  100,000  per  year  overall,  with  a  much  higher  inci-
ence  in  infants  than  in  children  (4.40  vs  0.34  cases  per
00,000)  [3].  The  majority  of  children  have  idiopathic  dis-
ase.  The  most  common  known  cause  is  myocarditis  (46%).
s  the  myocardium  may  fully  recover  from  viral  injury,  the
resence  of  myocarditis  has  been  described  to  be  a  pre-
ictive  factor  of  better  outcome  in  several  studies.  Indeed,
he  Paediatric  Cardiomyopathy  Registry  reported  a  5-year
ransplantation-free  rate  as  high  as  81%  in  individuals  with
yocarditis.  In  these  patients,  ECMO  can  be  initiated  to  rest
nd  unload  the  heart,  allowing  the  myocardium  to  recover
rom  injury,  as  a  bridge  to  recovery,  with  excellent  results.
ther  factors  indicating  better  prognosis  in  dilated  car-
iomyopathy  are  younger  age  at  diagnosis  and  higher  left
entricular  ejection  fraction.  If  the  myocardium  does  not
ecover,  ECMO  may  then  be  switched  to  a  long-term  means
f  MCS  until  heart  transplantation.
The  optimal  timing  for  initiating  MCS  is  before  circulatory
ollapse,  avoiding  end-organ  injury,  particularly  neurologi-
al  damage.  As  experience  with  this  therapy  has  increased,
he  threshold  for  initiating  MCS  has  been  lowered.  Cur-
ently,  MCS  should  be  considered  in  patients  in  heart  failure
equiring  a  progressive  increase  in  inotropic  support  (e.g.
pinephrine  > 0.3  g/kg/min  or  requirement  of  a  second
notrope),  cardiac  index  <  2.0  L/min/m2,  decreased  mixed
enous  saturation  (<  40%),  lactic  acidosis,  poor  end-organ
erfusion  evidenced  by  oliguria  (<  1  mL/kg/h),  altered  men-
al  status,  mechanical  ventilation  requirement,  inability  to
olerate  enteral  feeding,  rising  liver  enzymes,  rising  creati-
ine,  immobility  or  extreme  fatigue.  A  promising  alternative
trategy  in  these  potential  candidates  for  MCS  has  been
roposed  by  some  centres,  consisting  of  the  use  of  lev-
simendan  combined  with  milrinone  and  nesiritide,  while
inimizing  catecholamine  use  as  much  as  possible  and  keep-
ng  MCS  as  back-up.  MCS  was  delayed  or  avoided  in  a  small
eries  of  seven  patients  managed  with  this  strategy  [4].
ECMO  is  also  used  as  a  rescue  therapy  during  cardiac
rrest  refractory  to  conventional  cardiopulmonary  resus-
itation  (CPR).  In  this  indication,  ECMO  is  referred  to  as
xtracorporeal  cardiopulmonary  resuscitation  (ECPR).  The
urrent  American  Heart  Association  paediatric  advanced  life
upport  guidelines  recommend  consideration  of  ECPR  for  in-
ospital  paediatric  cardiac  arrest  patients  failing  to  respond
o  initial  resuscitation  attempts  ‘if  the  condition  leading  to
ardiac  arrest  is  reversible  or  amenable  to  heart  transplan-
ation’  [5].
The  other  indications  for  ECMO  are  intoxications  with
ardiodepressive  drugs,  life-threatening  arrhythmias  and
ypothermic  cardiac  arrest,  usually  due  to  cold-water
rowning.
urgical indications
he  most  common  indication  for  ECMO  is  failure  to  wean
rom  cardiopulmonary  bypass  after  repair  or  palliation  of
HD.  The  reported  frequency  of  ECMO  use  after  cardiopul-
onary  bypass  in  children  is  3—5%.  Left  VAD  may  be  used  as
n  alternative  to  ECMO  for  circulatory  support  after  failure
t
w
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o  wean  from  cardiopulmonary  bypass  in  patients  suspected
o  need  circulatory  support  for  a long  duration  (>  2  weeks),  if
hey  do  not  have  pulmonary  hypertension  or  respiratory  dys-
unction.  Patients  with  anomalous  origin  of  the  left  coronary
rtery  from  the  pulmonary  artery  are  a typical  example,  as
he  recovery  of  left  ventricular  function  may  be  delayed  for
onths  after  coronary  artery  surgical  reimplantation.
ontraindications
ontraindications  to  MCS  include  extreme  prematurity,  very
ow  birth  weight  (<  1.5  kg),  signiﬁcant  neurological  injury
nd  extracardiac  malformations  with  poor  prognosis.  Rel-
tive  contraindications  are  multisystem  organ  failure,  as
rgan  function  may  be  expected  to  improve  with  restoration
f  haemodynamic  stability,  and  chromosomal  aberrations.
ecisions  about  the  initiation  of  MCS  are  made  on  a  case-
y-case  basis  in  such  patients.
evices
xtracorporeal membrane oxygenation
CMO  circuits  are  composed  of  a  centrifugal  or  roller  pump
ith  a hollow-ﬁbre  or  membrane  oxygenator,  an  oxygen
lender,  a  pump  console,  a  heat  exchanger  and  a  pump
art.  The  site  of  cannulation  varies  with  the  indication  for
CMO.  Patients  requiring  support  in  the  immediate  post-
perative  period  are  cannulated  through  a  sternotomy,  via
ortic,  right  atrial  and  often  left  atrial  cannulae,  the  last
eing  for  decompression  of  the  left  ventricle.  Peripheral
annulation,  via  the  neck  in  infants  and  small  children  or
emoral  vessels  in  older  children,  is  preferred  in  non-surgical
atients.  The  circuit  may  be  primed  with  crystalloids  or
lood  products,  keeping  the  prime  volume  to  an  abso-
ute  minimum  to  decrease  the  effect  of  haemodilution.
fter  initiation,  ECMO  ﬂow  is  increased  to  achieve  a  goal
f  100—150  mL/kg/min.  Anticoagulation  is  provided  using
eparin  infusion  to  maintain  an  activated  clotting  time
f  180—240  seconds.  Mechanical  ventilation  support  should
e  continued  with  low  settings  while  on  ECMO  to  prevent
telectasis.  Regarding  the  duration  of  support,  ECMO  pro-
ides  only  short-term  support,  with  a  maximum  duration  of
5—21  days.
entricular assist devices
ADs  are  composed  of  inﬂow  and  outﬂow  cannulae,  a  pump
ystem,  a  power  source  and  a  system  controller.  The  inﬂow
annula  is  attached  to  the  left  atrium  (short-term  devices)
r  to  the  apex  of  the  left  ventricle  (long-term  devices)  and
lood  is  pumped  by  the  device  into  the  outﬂow  cannula,
hich  is  sutured  to  the  ascending  aorta.  When  a  right  VAD  is
ndicated,  the  inﬂow  cannula  is  attached  to  the  right  atrium
nd  the  outﬂow  cannula  into  the  main  pulmonary  artery.  In
ontrast  to  ECMO,  the  implantation  of  VAD  devices  requires
entral  cannulation  via  sternotomy  and,  in  the  case  of  long-
erm  devices,  cardiopulmonary  bypass.
The  VAD  devices  can  be  classiﬁed  as  short-  or  long-term,
ith  2  weeks  being  the  usual  limit  for  short-term  VADs.  The
jection  can  be  achieved  with  centrifugal,  pneumatic  pusher
Mechanical  circulatory  support  for  infants  and  small  children  
Figure 1. Examples of the three principal design types of ven-
tricular assist devices. A. Biomedicus: rotational centrifugal design;
blood is accelerated by centrifugal forces. B. MicroMed DeBakey VAD
Child: axial rotary design; a rotating impeller is suspended in a nar-
row housing and driven by an electrical motor; as the blood ﬂows
through the narrow chamber, it is continuously accelerated by the
blades of the impeller. C. EXCOR: pneumatic pulsatile pusher plate
design; the blood-ﬁlled chamber is externally compressed by an air-
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Eﬁlled chamber via a membrane; there is no contact between the
pumping mechanical parts (lower part) and the blood bag (upper
part).
plate  or  axial  ﬂow  pumps  (Fig.  1).  In  centrifugal  pumps,
blood  enters  in  the  centre  of  a  rotor  and  has  direct  contact
with  the  motor  parts  (Fig.  1A).  In  the  pneumatic  pusher  plate
systems,  blood  runs  through  a  closed  polyurethane  pouch
with  an  inlet  and  an  outlet  valve  (Fig.  1C).  The  blood-ﬁlled
pouch  is  separated  from  an  air-ﬁlled  chamber  by  a  thin  mem-
brane.  Compressed  air  drives  the  blood  out  of  the  pouch
in  systole,  and  negative  pressure  drives  the  blood  into  the
pouch  in  diastole.  The  resulting  ﬂow  is  pulsatile.  In  the  axial
design,  a  rotating  impeller  is  suspended  in  a  narrow  hous-
ing  and  driven  by  an  electrical  motor  (Fig.  1B).  As  blood
ﬂows  through  the  narrow  chamber,  it  is  continuously  accel-
erated  by  the  blades  of  the  impeller.  These  devices  have  a
low  proﬁle  and  may  be  implanted  in  a  large  blood  vessel.
Short-term  devices
Short-term  devices  are  usually  used  for  acute  processes
such  as  myocarditis,  postoperative  ventricular  dysfunction
or  acute  graft  rejection,  with  a  hope  of  bridging  to  recov-
ery.  Another  emerging  indication  for  short-term  devices  is
‘bridge  to  decision’,  when  a  patient  clearly  needs  MCS,  but
has  signiﬁcant  end-organ  dysfunction  with  uncertain  prog-
nosis  that  may  affect  transplantation  eligibility.
Short-term  VADs  are  centrifugal  pumps.  The  devices
in  general  use  nowadays  are  the  Biomedicus  Biopump
b
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Medtronic,  Minneapolis,  MN,  USA)  (Fig.  1A),  the  Rotaﬂow
Maquet  Cardiovascular,  Wayne,  NJ,  USA)  and  the  Thoratec
ediMag  (formerly  Levitronix  PediMag/CentriMag;  Thoratec
o.,  Pleasanton,  CA,  USA),  designed  for  small  infants  weigh-
ng  as  little  as  3  kg.  Central  cannulation  via  sternotomy
n  the  left  atrium  and  the  aorta  without  going  into  car-
iopulmonary  bypass  is  recommended  to  provide  optimal
ircuit  ﬂow.  Compared  with  an  ECMO  circuit,  these  VADs
ave  the  advantage  of  a  lower  priming  volume,  and,  due
o  the  absence  of  oxygenator  or  venous  reservoirs,  lower
eparin  requirements  and  reduced  trauma  to  red  blood
ells.  Limitations  of  the  centrifugal  pumps  are  that  only
hort-term  support  is  provided,  requiring  a  conversion  to  a
ong-term  VAD  if  recovery  is  not  successful  after  2—3  weeks.
n  addition,  sedation  and  mechanical  ventilation  have  to  be
ontinued.
ong-term  devices
he  Berlin  Heart  VAD  or  EXCOR  is  a  paracorporeal  pneumati-
ally  driven  pulsatile-ﬂow  VAD.  It  is  the  only  device  suitable
or  all  paediatric  patients,  including  neonates,  and  is  capa-
le  of  providing  both  left  VAD  and  biventricular  VAD  support.
t  is  available  with  ﬁve  pumping  chamber  sizes  (10—60  mL).
he  blood  pump  is  transparent,  allowing  visual  control  of
lling,  emptying  and  thrombus  formation  (Fig.  1C).  The
lood-contacting  surfaces  of  the  pump  are  heparin-coated,
educing  anticoagulation  requirements.  Patients  implanted
ith  a  Berlin  Heart  no  longer  need  mechanical  ventilation,
an  resume  enteral  feeding  and,  although  they  have  to
emain  hospitalized,  are  ambulatory  (Fig.  2).  The  duration
f  support  may  extend  up  to  400  days.
The  Thoratec  VAD  is  another  paracorporeal  pneumatic
AD,  implantable  in  children  aged  ≥  7  years  of  age  with  a
ody  surface  area  >  0.7  m2.
Apart  from  the  EXCOR  and  Thoratec  VADs,  long-term
evices  suitable  for  school-age  children  (body  surface  area
.7—1.5  m2) are  the  MicroMed  DeBakey  VAD  Child  and  the
biomed  BVS  5000,  both  of  which  are  axial  ﬂow  pumps.
hese  devices  allow  ambulation  and  rehabilitation  during
upport,  but  are  capable  of  providing  left-sided  support  only.
The  main  differences  between  ECMO  and  the  Berlin  Heart
XCOR  (the  VAD  most  commonly  used  in  children)  are  sum-
arized  in  Table  1.
utcomes
xtracorporeal membrane oxygenation
nformation  on  outcomes  after  ECMO  has  been  collected  by
he  international  Extracorporeal  Life  Support  Organization
egistry  since  1989.  This  registry  has  collected  data  on  over
7,000  patients  so  far,  analysed  with  a  speciﬁc  focus  on
eonatal  and  paediatric  cardiac  patients,  accounting  for
9%  of  all  cases  recorded  [6].  The  main  complications  of
CMO  are  intracranial  or  surgical  site  bleeding,  thromboem-
olic  events,  haemolysis,  infections  and  renal  failure,  all
f  which  have  a  signiﬁcant  impact  on  survival.  A  signiﬁcant
imitation  of  the  registry  is  the  absence  of  functional  assess-
ent  and  long-term  neurological  follow-up.  Fortunately,
402  V.  Gournay,  Q.  Hauet
Table  1  Characteristics  of  the  two  main  types  of  paediatric  mechanical  circulatory  support.
ECMO  EXCOR
Patient  size  Any  >  2.5  kg
Experience  Thousands  of  paediatric  cases  since
1975
Hundreds  of  paediatric  cases  since
the  early  1990s  in  Europe  and  the
early  2000s  in  the  USA
Setting  Intensive  care  unit,  mechanical
ventilation
Ambulation  and  rehabilitation
possible
Anticoagulation  Strictly  required Reduced  need
Maximum  duration  of  support  15—21  days  >  400  days
Respiratory  support  Yes  No
Biventricular  support  Always  Possible
Flow  type  Non-pulsatile  Pulsatile
Complications  (neurological  injury)  High  Low
ECMO: extracorporeal membrane oxygenation; EXCOR: paediatric ventricular assist device.
several  publications  have  addressed  the  issue  of  long-term
neurological  outcome  after  ECMO,  particularly  after  ECPR.
Post-surgical  extracorporeal  membrane
oxygenation
Three  large  series  have  reported  outcomes  of  children  with
postcardiotomy  myocardial  dysfunction  requiring  ECMO,  in
180  patients  (median  age  109  days),  66  patients  (mean  age
Figure 2. Eight-year-old patient 1 month after surgical implan-
tation of an EXCOR left ventricular assist device; she was feeding
correctly and was able to walk around within the ward.
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ﬂ.2  years)  and  58  patients  (mean  age  12  days),  respectively
7—9].  Failure  to  wean  from  cardiopulmonary  bypass,  fol-
owed  by  low  cardiac  output  and  pulmonary  hypertension,
ere  the  main  indications  for  ECMO.  The  duration  of  ECMO
upport  ranged  from  5  to  6  days.  Survival  to  hospital  dis-
harge  ranged  from  38%  to  45%.  Overall,  26  out  of  244
10.6%)  survivors  of  ECMO  required  heart  transplantation,
ith  no  heart  transplantation  being  a  predictor  of  mor-
ality.  The  major  complication  of  postcardiotomy  ECMO
as  haemorrhage,  frequently  requiring  reintervention.  Pro-
onged  ECMO  duration  and  renal  failure  were  consistent
redictors  of  mortality  in  the  three  studies.  Complete  oper-
tive  repair  tended  to  be  associated  with  improved  survival
ompared  with  palliative  surgery.  One  should  also  keep  in
ind  that  any  signiﬁcant  residual  lesion  has  to  be  ruled  out
hen  a  patient  remains  dependent  on  support  after  surgery.
xtracorporeal  cardiopulmonary  resuscitation
ourteen  studies  have  reported  on  762  patients  treated
ith  ECPR  from  1990  to  2008,  with  cumulative  hospital  sur-
ival  in  371  (49%),  ranging  in  individual  reports  from  33%
o  79%  [1,10,11]. The  most  consistent  predictors  of  mor-
ality  found  in  several  studies  were  non-cardiac  disease,
enal  dysfunction  on  ECMO,  neurological  complications  on
CMO  and  lowest  pH  on  ECMO.  Unexpectedly,  conventional
PR  duration  before  ECPR  initiation  was  not  a  predictor  of
ortality  in  nine  of  the  studies.  Survival  without  gross  neu-
ological  impairment  has  even  been  reported  in  patients
fter  prolonged  chest  compression  for  up  to  176  minutes,
o  a  maximum  duration  of  CPR  beyond  which  ECPR  is  not
eneﬁcial  cannot  be  determined.  Furthermore,  in  a  review
f  the  Extracorporeal  Life  Support  Organization  database,
lthough  pre-ECMO  arterial  pH  was  strongly  associated  with
utcome,  12%  of  children  of  the  survivors  had  a  pre-ECMO
H  <  6.9  [11].  The  quality  of  CPR,  as  well  as  the  delay
etween  the  cardiac  arrest  and  CPR  initiation,  are  more
ikely  to  inﬂuence  mortality  than  CPR  duration.  Another
actor  is  the  underlying  pathological  condition,  which  may
ffect  the  quality  of  resuscitation.  For  example,  patients
ith  complex  cardiac  anatomy  precluding  effective  blood
ow  supply  and  oxygen  delivery  to  the  brain  during  CPR,
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such  as  blocked  aortopulmonary  shunts,  are  more  likely  to
suffer  fatal  ischaemic  brain  injury.
Neurological  outcome  in  ECPR  survivors  was  mostly
assessed  by  the  Paediatric  Cerebral  Performance  Category
score,  which  rates  disability  from  1  (normal)  to  6  (brain
death).  In  the  nine  studies  in  which  this  information  was
available,  the  Paediatric  Cerebral  Performance  Category
score  was  ≤  2  (indicating  no  or  only  mild  dysfunction)  in  161
out  of  204  survivors  (79%).
Thus,  acceptable  survival  and  neurological  outcome
can  be  achieved  with  ECPR  in  children  after  a  prolonged
witnessed  cardiac  arrest  refractory  to  conventional  resus-
citation  measures.  However,  these  results  can  not  be
generalized  to  ECPR  rewarming  protocols  after  hypothermic
arrest,  usually  due  to  cold-water  drowning,  initiated  after
an  ill-deﬁned  delay  in  patients  found  pulseless,  in  whom  a
survival  of  only  22%  was  reported  recently  [12].
Early  and  adequate  CPR,  as  well  as  rapid  ECMO  deploy-
ment  requiring  immediate  staff  and  resource  availability,
are  of  utmost  importance  to  ensure  good  results  with  this
technique.
Myocarditis
An  analysis  of  data  from  the  Extracorporeal  Life  Support
Organization  registry  focused  on  ECMO  in  patients  with  acute
myocarditis  [13].  Of  19,348  reported  paediatric  ECMO  uses
from  1995  to  2006,  260  runs  were  for  255  patients  with
myocarditis.  Of  these,  155  (61%)  survived  to  hospital  dis-
charge,  with  rates  of  96%  for  recovery  and  4%  for  heart
transplantation.  Female  sex,  arrhythmia  on  ECMO  and  need
for  dialysis  during  ECMO  were  independent  risk  factors  for
in-hospital  mortality.  Strokes  occurred  in  8.2%  of  patients
and  brain  death  occurred  in  6%  of  patients.
Bridge  to  transplantation
A  few  retrospective  studies  have  reported  the  outcomes  of
patients  supported  by  ECMO  while  awaiting  transplantation
[14—17].  The  size  of  the  series  ranged  from  21  to  47  patients.
The  average  duration  of  support  varied  from  6  to  20  days,
with  extremes  going  up  to  85  days.  Mortality  on  waiting  list
was  around  35%  and  survival  to  discharge,  after  either  suc-
cessful  weaning  or  transplantation,  ranged  from  45%  to  55%.
Patients  with  cardiomyopathies  and  myocarditis  had  bet-
ter  chances  of  favourable  outcome  than  those  with  CHD,
whereas  older  age  and  renal  insufﬁciency  were  risk  factors
for  poor  outcome.
In addition,  an  analysis  of  the  United  Network  for  Organ
Sharing  database  reported  the  outcome  of  2532  transplan-
tations  in  children,  171  (6.8%)  of  whom  were  supported
by  ECMO  while  awaiting  transplantation  [18]. Patients
receiving  ECMO  had  a  higher  incidence  of  posttransplanta-
tion  complications  (cardiac  reoperation,  need  for  dialysis,
infection,  stroke)  before  discharge  than  those  with  VADs,
resulting  in  a  higher  30-day  posttransplantation  mortality.
Ventricular assist devicesThe  largest  single-centre  experience  with  the  EXCOR  (94
children)  has  been  reported  recently  by  Hetzer  et  al.  from
the  Berlin  Heart  Institute  [2].  In  this  report,  the  authors
divided  their  nearly  20-year  period  into  two  time  periods;
n
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hey  showed  signiﬁcant  improvements  in  survival  over  the
ears,  as  the  success  rate  (transplantation  or  successful
eaning)  increased  from  49%  in  the  ﬁrst  decade  (1990—2001)
o  69%  in  the  later  era  (2002—2011).  The  improvement  was
ven  more  marked  in  infants.  The  authors  attributed  these
mprovements  to  earlier  implantations  of  VADs  and  modiﬁ-
ations  in  the  management  of  anticoagulation.  Indeed,  the
ncidence  of  thrombotic  adverse  events  decreased  signiﬁ-
antly.
In  North  America,  the  EXCOR  only  became  available  in
004,  initially  as  a  result  of  compassionate  appeals  to  the
ood  and  Drug  Administration.  Since  that  date,  its  use  has
rown  exponentially,  as  more  than  200  children  have  been
mplanted  in  North  America.  Extensive  data  regarding  the
utcome  of  these  children  have  been  reported  in  two  large
ulticentre  studies  [19,20]. The  ﬁrst  study  was  the  Berlin
eart  Investigation  Device  Exemption  trial,  referred  to  as
he  IDE  trial,  which  was  conducted  in  17  centres  between
007  and  2010,  comparing  the  safety  and  effectiveness  of
he  EXCOR  in  a  carefully  selected  cohort  of  children,  with
 historical  control  population  supported  with  ECMO  as  a
ridge  to  transplantation  [20].  The  48  study  subjects  were
ivided  into  two  groups  based  on  body  surface  area  (<  0.7  m2
nd  >  0.7  m2).  In  both  groups,  survival  time  on  support  was
igniﬁcantly  longer  in  patients  supported  with  the  EXCOR
han  in  those  on  ECMO.  Overall,  approximately  90%  of  the
atients  in  both  groups  achieved  a  favourable  outcome,
ostly  with  heart  transplantation.  Upon  successful  comple-
ion  of  this  trial,  the  EXCOR  was  granted  approval  in  the
SA  in  late  2011.  The  90%  survival  of  the  IDE  trial  is  seem-
ngly  very  high  compared  with  the  European  experience  and
re  IDE  trial  results  in  the  USA.  However,  the  data  from
he  IDE  trial  do  not  necessarily  reﬂect  real-world  experi-
nce.  Indeed,  they  do  not  capture  the  experience  of  >  75%
f  all  children  in  the  USA  implanted  with  the  EXCOR  on
ompassionate-use  access  during  the  same  period,  who  were
ot  enrolled  in  the  IDE  trial  because  they  met  one  or  more
xclusion  criteria  or  because  they  were  implanted  at  one
f  the  27  non-IDE  study  sites.  Hence,  the  second  large  mul-
icentre  North  American  study  was  conducted  in  order  to
haracterize  the  performance  of  the  EXCOR  in  unselected
atients  [19]. In  this  study,  Almond  et  al.  analysed  the  larger
ompassionate-use  cohort  (156  subjects)  combined  with  the
8  original  IDE  trial  subjects.  The  median  duration  of  sup-
ort  was  40  days  (range  1—435  days).  As  expected,  12-month
urvival  in  this  unselected  population  was  lower  than  that
n  the  IDE  trial  (75%,  comprising  64%  who  reached  trans-
lantation,  6%  who  recovered  and  5%  who  were  alive  on  the
evice).  Neurological  dysfunction  (mostly  from  thromboem-
olic  events)  occurred  in  29%  and  was  the  leading  cause  of
eath.  Other  serious  adverse  events  were  major  bleeding
44%),  major  infection  (46%)  and  respiratory  failure  (29%).
ultivariable  analysis  identiﬁed  lower  weight,  end-organ
ysfunction  reﬂected  by  renal  and  hepatic  dysfunction,  and
iventricular  support  as  risk  factors  for  mortality.  In  con-
rast  to  other  studies,  ECMO  before  EXCOR  implantation  was
ot  a  risk  factor  in  this  model.  It  is  possible  that  ECMO,
hen  used  strictly  for  short-term  resuscitative  support  to
ormalize  end-organ  function  before  VAD  implantation,  may
mprove  VAD  candidacy  in  selected  patients.  This  duality  of
ffect  for  ECMO  may  account  for  its  absence  in  the  ﬁnal
ultivariable  model.
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The  absence  of  inﬂuence  of  ECMO  on  in-hospital  mor-
ality  was  also  reported  in  a  retrospective  cohort  study
erformed  between  2004  and  2011  in  all  children  listed  for
eart  transplantation  requiring  EXCOR  implantation  in  the
wo  UK  paediatric  heart  transplantation  centres  [21]. During
his  7-year  period,  102  children  required  EXCOR  support.  Of
hese,  86  (84%)  survived  to  transplantation  (n  =  74)  or  EXCOR
xplantation  (n  =  12)  and  81%  survived  to  discharge.  Neither
ge,  ECMO  use  nor  duration  of  support  inﬂuenced  outcome.
troke,  ongoing  requirement  for  ventilation  while  on  EXCOR
nd  diagnosis  other  than  dilated  cardiomyopathy  were  the
nly  independent  mortality  risk  factors.  The  proportion  of
hildren  undergoing  heart  transplantation  bridged  with  an
XCOR  has  increased  over  time  from  12.3%  in  2004  to  59%
n  2011.
otential consequences of the
evelopment of mechanical circulatory
upport
n  important  issue  is  that  the  average  waiting  time  on  the
ransplant  list  is  doomed  to  increase  in  the  current  setting
f  static  organ  supply  as  the  number  of  children  supported
ith  a  VAD  before  heart  transplantation  increases.  This
as  indeed  one  of  the  conclusions  drawn  from  the  UK
xperience  [21].  Given  the  high  risk  of  thromboembolic
trokes  and  bleeding  while  on  EXCOR,  the  likelihood  of  suc-
essful  outcome  may  decrease  as  support  duration  extends.
his  should  be  taken  in  consideration  when  determining
he  optimal  timing  of  EXCOR  implantation.  The  dilemma
or  clinicians  is  the  fact  that  the  appropriate  time  for
mplantation  between  ‘too  early’  and  ‘too  late’  for  this
evice  is  difﬁcult  to  determine.
Another  potential  drawback  of  MCS  could  be  a  higher
isk  of  rejection  after  transplantation  due  to  human  leuko-
yte  antogen  sensitization,  induced  by  exposure  to  blood
roducts  while  supported.  However,  based  on  the  above-
entioned  analysis  (the  United  Network  for  Organ  Sharing
atabase  of  2532  paediatric  transplantations,  17%  of  whom
ere  supported  at  the  time  of  transplantation  [either  VAD,
CMO,  or  intra-aortic  balloon  pump]),  the  use  of  a  VAD  does
ot  predict  higher  posttransplantation  mortality  in  paedi-
tric  patients  [18].  Ten-year  posttransplantation  survival  for
ll  patients  was  approximately  57%.  In  this  population,  the
eed  for  ECMO,  but  not  the  need  for  a  VAD,  was  a  strong  pre-
ictor  of  30-day  mortality,  reﬂecting  poor  clinical  and  func-
ional  status.  ECMO  ceased  to  be  a  predictor  of  poor  outcome
mong  patients  surviving  the  initial  30  days,  and  the  survival
urves  were  parallel  in  ECMO,  VAD  and  non-assisted  patients.
hus,  those  patients  who  reach  transplantation  with  ade-
uate  end-organ  function  and  survive  the  perioperative
eriod  appear  to  have  similar  long-term  outcomes,  regard-
ess  of  the  need  for  MCS.  These  ﬁndings  suggest  that  MCS
oes  not  increase  the  risk  of  rejection  after  transplantation.uture developments
n  the  mid  2000s,  the  growing  recognition  of  increasing  num-
ers  of  children  with  heart  failure  prompted  the  National
RV.  Gournay,  Q.  Hauet
eart,  Lung  and  Blood  Institute  in  the  USA  to  launch  a
rogramme  with  the  aim  of  developing  a  novel  circulatory
upport  device  for  children  weighing  2—25  kg.  The  technical
equirements  for  these  devices  were:  rapid  deployment
<  1  hour  after  decision  to  initiate  support);  minimal  priming
olume  and  blood  product  exposure;  ﬂexible  cannulation
o  accommodate  anatomical  variants;  minimize  risk  of
omplications,  including  infection,  bleeding,  haemolysis
nd  thrombosis;  long-term  support  up  to  6  months  after
nsertion.
The  Pumps  For  Kids,  Infants  and  Neonates  (PumpKIN)  pro-
ramme  provided  ﬁnancial  support  for  the  preclinical  testing
f  four  promising  devices  [22,23]. One  of  the  programmes
PediaFlow  Pediatric,  Pittsburgh)  has  ended  secondary  to
 lack  of  industry  partner,  but  three  are  currently  in  the
n-vitro  or  early  stages  of  in-vivo  testing  in  animal  models.
linical  trials  are  anticipated  in  the  next  few  years.
Jarvik  Heart,  in  collaboration  with  the  University  of  Mary-
and,  is  redesigning  the  Jarvik  2000  axial  ﬂow  pump  for
aediatric  use  in  infants.  It  is  extremely  small  with  a  priming
olume  of  1  mL  and  sits  inside  the  ventricle  wall.
Both  the  Paediatric  Cardiopulmonary  Assist  System
Ension)  and  the  Pedi  PumpLung  (Levitronix  in  collaboration
ith  the  University  of  Maryland)  will  be  self-contained
evices  capable  of  pumping  and  oxygenating  blood
imultaneously.
onclusion
ith  the  number  of  children  in  end-stage  heart  failure
rowing  disproportionately  to  the  stagnant  organ  supply  in
ransplantation  programmes,  the  need  for  development  of
CS  devices  that  are  safe  and  sustainable  for  the  paedi-
tric  population  is  becoming  more  pressing.  Considerable
rogress  has  been  achieved  in  this  ﬁeld  over  the  last  two
ecades.  The  use  of  ECMO  ﬁrst  and  then  VADs,  mostly  the
XCOR,  has  grown  exponentially  worldwide  to  offer  children
nd  infants  life-saving  support.  This  support  can  be  either
emporary  as  a  bridge  to  recovery  after  a cardiac  arrest
r  postcardiotomy  failure,  or  prolonged  for  several  months
s  a  bridge  to  transplantation  in  the  absence  of  recovery.
owever,  the  high  rate  of  complications,  particularly  throm-
oembolic  strokes  and  bleeding,  remains  a  concern.  Further
esearch  to  develop  safer  miniaturized  devices  and  improve
nticoagulation  management  is  thus  warranted.  Indeed,
he  optimal  timing  for  implantation  remains  a  major  issue
or  clinicians,  considering  the  high  risk  of  life-threatening
dverse  events,  as  the  average  waiting  time  for  transplan-
ation  on  VAD  support  is  steadily  extending.
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